Oncology Clinical Trials: A Leading Driver Behind Increasing Cancer Incidence Fueling The Growth Of The Market Due To Rising Prevalence Of Unhealthy Lifestyle Habits Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Oncology Clinical Trials Industry Market Size Be by 2025?
In recent times, the oncology clinical trials market has witnessed substantial growth. The market size is expected to rise from $14.04 billion in 2024 to $14.99 billion in 2025, translating to a compound annual growth rate (CAGR) of 6.8%. The growth experienced in the past can be ascribed to the escalating number of cancer incidents, the expanding adoption of targeted cancer treatments, the growing awareness about early detection and screening of cancer, the increasing number of clinical research organizations focusing on oncology, and the rise in patient involvement via advocacy groups.

What's the Long-Term Growth Forecast for the Oncology Clinical Trials Market Size Through 2029?
A substantial expansion is anticipated in the oncology clinical trials market in the upcoming years, culminating in a market value of $19.22 billion by 2029, with a compound annual growth rate (CAGR) of 6.4%. The notable growth within this period can be linked to an escalating demand for tailored precision treatments for cancer, a heightened focus on rare and orphan cancer indications, a surge in the use of decentralized and virtual cancer trials, as well as the increasing utility of genomic sequencing in the selection of trial patients. The forecast period will also witness distinct trends including progress in biomarker-based studies, advancement in data analytics applied to trial design, breakthroughs in immuno-oncology therapies, infusion of artificial intelligence and machine learning, progression in patient-focused trial models, and inclusion of real-world data in trial assessment.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oncology-clinical-trials-global-market-report

What Are the Key Growth Drivers Fueling the Oncology Clinical Trials Market Expansion?
The surge in the occurrences of cancer is anticipated to fuel the progression of the oncology clinical trials market. The term 'cancer incidence' pertains to the count of novel cancer cases taking place in a particular demographic during a set amount of time. Unhealthy lifestyle practices such as poor eating habits, lack of physical activity, tobacco consumption, and heavy drinking are the primary contributors to the rising cancer incidence, heightening the likelihood of various cancers. Oncology clinical trials push forward the treatment of cancer by examining new therapies and procedures, enhancing patient results via evidence-supported research. These trials speed up medical advancements by testing both safety and effectiveness, thus promoting improvement in cancer prevention, diagnosis, and treatment. For example, as per the Australian Institute of Health and Welfare - a government agency based in Australia - the cancer cases identified in Australia went up to 160,570 in 2022 from 156,781 in 2021, a rise by 3,789 cases. Hence, the rising cancer incidence facilitates the expansion of the oncology clinical trials market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27371&type=smp

Which Emerging Trends Are Transforming the Oncology Clinical Trials Market in 2025?
Leading enterprises in the oncology clinical trials market are concentrating on the creation of high-tech solutions, like advanced bioinformatics platforms. Such platforms augment the analysis of data, hasten the process of patient enrolment, and optimize the outcomes of the trials. The advanced bioinformatics platforms are complex software systems which utilize computational tools and algorithms to amass, scrutinise and decipher intricate biological and clinical data for research and healthcare applications. For instance, in the year 2023's September, Deep 6 AI, a healthcare technology enterprise based in the US, introduced an AI-based genomics module. The goal of this module was to accelerate enrollment in precision medicine and oncology clinical trials. The module applies artificial intelligence and natural language processing to derive both structured and unstructured genomics data from electronic medical records. This enables the real-time detection and accurate matching of patients with particular genetic markers. Consequently, researchers are provided with the capability to scour millions of records for more than 19,000 genes and 30,000 mutation names, thus vastly speeding up the recruitment of patients and improving the efficacy of clinical trial design.

How Is the Oncology Clinical Trials Market Segmented?
The oncology clinical trials market covered in this report is segmented

1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Expanded Access
3) By Therapeutic Modality: Immunotherapy, Targeted Therapy, Chemotherapy, Cell And Gene Therapy, Other Therapeutic Modalities
4) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Other Indications
5) By Sponsor Type: Pharmaceutical And Biotech Companies, Academic And Research Institutes, Government Organizations, Other Sponsor Types

Subsegments:
1) By Phase I: Safety And Dosage Studies, Pharmacokinetics And Pharmacodynamics Studies, Biomarker Identification Studies
2) By Phase II: Efficacy And Side Effects Studies, Dose-Response Relationship Studies, Therapeutic Effectiveness Studies
3) By Phase III: Large-Scale Efficacy Studies, Comparative Effectiveness Studies, Multicenter Randomized Controlled Trials
4) By Phase IV: Post Marketing Surveillance Studies, Long-Term Safety Studies, Quality Of Life Studies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27371&type=smp

Which Companies Are Leading the Charge in Oncology Clinical Trials Market Innovation?
Major companies operating in the oncology clinical trials market are Pfizer Inc., Johnson & Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Genentech Inc., BeiGene Ltd., Seagen Inc.

Which Regions Are Leading the Global Oncology Clinical Trials Market in Revenue?
North America was the largest region in the oncology clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27371
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.